Month: September 2022

Silence Therapeutics (NASDAQ:SLN), Alnylam Pharmaceuticals (NASDAQ:ALNY), Eli Lilly (NYSE:LLY), Amryt Pharma (NASDAQ:AMYT), SCYNEXIS (NASDAQ:SCYX), SINTX Technologies (NASDAQ:SINT), Ocuphire Pharma (NASDAQ:OCUP), Regeneron Pharmaceuticals (NASDAQ:REGN), VistaGen Therapeutics (NASDAQ:VTGN), Axsome Therapeutics (NASDAQ:AXSM), Lyra Therapeutics (NASDAQ:LYRA), Revance Therapeutics (NASDAQ:RVNC) – Important Biotech Catalysts For September 8, 2022 – End Of The Day Summary

[ad_1] The United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ RVNC lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of moderate to severecfrown lines…